Company intelligence
Matica Biotechnology, Inc.
Your CDMO for gene therapy and viral vectors
About Matica Biotechnology, Inc.
Matica Biotechnology, Inc. is a contract development and manufacturing organization (CDMO) specializing in the production of viral vectors and gene therapies. Our exceptional team of industry veterans, with over 15 years of experience, has a proven track record in delivering innovative products to the clinic and market. At Matica Bio, our mission is to provide a streamlined, global manufacturing solution for our clients' products. Our state-of-the-art single-use bioreactor platforms, remote monitoring systems, quality-driven processes, and dedicated staff work together seamlessly to ensure a reliable and efficient product development and manufacturing process. Our unwavering focus on quality, compliance, and patient safety allows us to meet the often-accelerated clinical approval pathways, getting our clients' products to the patient bedside quickly and efficiently. Trust Matica Bio to be your partner in advancing healthcare through advanced therapies.
Verified activity
Signals from Matica Biotechnology, Inc.
4 published signals
Research & Knowledge
Matica Biotechnology, Inc. reported that a St. Jude team co-delivered lentiviral vectors with Cas9-containing virus-like particles to generate gene-edited CAR-T cells achieving greater than 70% editing across multiple targets while recovering roughly twice as many cells as electroporation in the head-to-head comparison.
Reported by John Childers
Research & Knowledge
Matica Biotechnology, Inc. demonstrated a microfluidic clarification system for lentiviral vector harvest achieving greater than 95% vector recovery and greater than 95% cell removal while avoiding product losses commonly associated with depth filtration.
Reported by John Childers
Research & Knowledge
Matica Biotechnology, Inc. published a new study using deep learning-guided Raman spectroscopy to predict lentiviral vector titer, viable cell density, glucose, and lactate in real time significantly outperforming traditional partial least squares models.
Reported by John Childers
Research & Knowledge
Matica Biotechnology, Inc. published a new AAV study combining spent-media metabolomics with multivariate data analysis to identify metabolites associated with higher vector titers and guide production-media optimization.
Reported by John Childers